These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 30659143

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
    Tan M, Zhang Q, Yuan X, Chen Y, Wu Y.
    J Exp Clin Cancer Res; 2019 Jul 15; 38(1):308. PubMed ID: 31307525
    [Abstract] [Full Text] [Related]

  • 4. Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML.
    Lei YC, Chen XJ, Dai YT, Dai B, Wang JY, Li MH, Liu P, Liu H, Wang KK, Jiang L, Chen B.
    Acta Pharmacol Sin; 2024 Mar 15; 45(3):633-645. PubMed ID: 38017299
    [Abstract] [Full Text] [Related]

  • 5. Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis.
    Qiu Y, Bai L, Zhao H, Mei X.
    BMC Cancer; 2024 Apr 24; 24(1):520. PubMed ID: 38658865
    [Abstract] [Full Text] [Related]

  • 6. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
    Chen LT, Chen CT, Jiaang WT, Chen TY, Butterfield JH, Shih NY, Hsu JT, Lin HY, Lin SF, Tsai HJ.
    Mol Cancer Ther; 2016 Oct 24; 15(10):2323-2333. PubMed ID: 27512117
    [Abstract] [Full Text] [Related]

  • 7. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
    Fischer J, Rossetti S, Datta A, Eng K, Beghini A, Sacchi N.
    Mol Cancer; 2015 Jan 23; 14():7. PubMed ID: 25612891
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. XPO1 is a new target of homoharringtonine (HHT): Making NPMc+ AML cells much more sensitive to HHT treatment.
    Xue J, Chu P, Gao W, Wang F, Gao Y, Liu S, Kang Z, Yan J, Wang H.
    Biochem Biophys Res Commun; 2023 Oct 01; 675():155-161. PubMed ID: 37473530
    [Abstract] [Full Text] [Related]

  • 10. [Synergistic effect of azacitidine with homoharringtonine by activating the c-MYC/DDIT3/PUMA axis in acute myeloid leukemia].
    Li J, Huang YQ, Zi J, Song CH, Ge Z.
    Zhonghua Xue Ye Xue Za Zhi; 2023 Dec 14; 44(12):1001-1009. PubMed ID: 38503523
    [Abstract] [Full Text] [Related]

  • 11. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.
    Nguyen T, Parker R, Zhang Y, Hawkins E, Kmieciak M, Craun W, Grant S.
    BMC Cancer; 2018 Nov 16; 18(1):1129. PubMed ID: 30445933
    [Abstract] [Full Text] [Related]

  • 12. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
    Chen P, Zhan W, Wang B, You P, Jin Q, Hou D, Wang X, You R, Zou H, Chen Y, Huang H.
    Exp Cell Res; 2019 Mar 15; 376(2):114-123. PubMed ID: 30763586
    [Abstract] [Full Text] [Related]

  • 13. Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia.
    Suo S, Zhao D, Li F, Zhang Y, Rodriguez-Rodriguez S, Nguyen LXT, Ghoda L, Carlesso N, Marcucci G, Zhang B, Jin J.
    Blood; 2024 Sep 19; 144(12):1343-1347. PubMed ID: 38968151
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.
    Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, Sun X, Wu Y, Zhou J, Pan J.
    Cancer Res; 2010 Mar 15; 70(6):2516-27. PubMed ID: 20215516
    [Abstract] [Full Text] [Related]

  • 16. The efficacy and safety of a homoharringtonine-based protocol for children with acute myeloid leukemia: A retrospective study in China.
    Tang Y, Luo C, Shen S, Xue H, Pan C, Hu W, Chen X, Cai J, Chen J, Tang J.
    Pediatr Hematol Oncol; 2021 Mar 15; 38(2):97-107. PubMed ID: 33016804
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia.
    Larizza L, Magnani I, Beghini A.
    Leuk Lymphoma; 2005 Feb 15; 46(2):247-55. PubMed ID: 15621809
    [Abstract] [Full Text] [Related]

  • 19. Repurposing a plant alkaloid homoharringtonine targets insulinoma associated-1 in N-Myc-activated neuroblastoma.
    Chen C, Wu J, Hicks C, Lan MS.
    Cell Signal; 2023 Sep 15; 109():110753. PubMed ID: 37301315
    [Abstract] [Full Text] [Related]

  • 20. Downregulation of c-Myc determines sensitivity to 2-methoxyestradiol-induced apoptosis in human acute myeloid leukemia.
    Chow JM, Liu CR, Lin CP, Lee CN, Cheng YC, Lin S, Liu HE.
    Exp Hematol; 2008 Feb 15; 36(2):140-8. PubMed ID: 18206725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.